Zynerba Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Zynerba gets 180-day Nasdaq bid-price extension, transfers to Capital Market

Zynerba Pharmaceuticals, Inc.

Nasdaq granted 180-day extension until Oct 30, 2023 to regain $1 bid price compliance.
Company's stock transferred from Nasdaq Global Market to Capital Market effective May 4, 2023.
Will consider reverse stock split to cure deficiency if needed.
Previously received deficiency notice Nov 1, 2022; failed to cure by May 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Zynerba Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

May 2, 2023, Nasdaq notified the Company that it had granted the Company an additional 180 calendar day period, or until October 30, 2023 (the “ Extended Compliance Date ”), to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on, among other things, (1) the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing requirements for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and (2) the Company’s written notice of its intention to cure the deficiency by effecting a reverse stock sp

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-056002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.